Advanced in Agranulocytosis

Dr. Sumithira Vasu

Hematology | Transplant Surgery
Osu Internal Medicine LLC
3900 Stoneridge Ln, 
Dublin, OH 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
19 Years of Experience
Advanced in Agranulocytosis
Osu Internal Medicine LLC
3900 Stoneridge Ln, 
Dublin, OH 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Sumithira Vasu is a Hematologist and a Transplant Surgeon in Dublin, Ohio. Dr. Vasu has been practicing medicine for over 19 years and is rated as an Advanced provider by MediFind in the treatment of Agranulocytosis. Her top areas of expertise are Acute Myeloid Leukemia (AML), Graft Versus Host Disease (GvHD), Myelodysplastic Syndrome (MDS), Bone Marrow Transplant, and Islet Cell Transplantation. Dr. Vasu is currently accepting new patients.

Her clinical research consists of co-authoring 119 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 4 articles in the study of Agranulocytosis.

Specialties
Hematology
Transplant Surgery
Licenses
Internal Medicine in OH
Hospital Affiliations
Ohio State University State Health System
Languages Spoken
English
Tamil
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Buckeye Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
CareFirst
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medical Mutual
  • HMO
  • PPO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 8 Less Insurance Carriers -

Locations

OSU INTERNAL MEDICINE LLC
3900 Stoneridge Ln, Dublin, OH 43017
Other Locations
OSU INTERNAL MEDICINE LLC
410 W 10th Ave, Doan 110, Columbus, OH 43210

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

Pilot Study of Haploidentical or Matched Donor Virus-Specific T-cells (Cytomegalovirus (CMV) or Adenovirus (AdV)) to Treat CMV or AdV Reactivation or Disease in Patients After Solid Organ or Hematopoietic Stem Cell Transplantation (HCT)
Pilot Study of Haploidentical or Matched Donor Virus-Specific T-cells (Cytomegalovirus (CMV) or Adenovirus (AdV)) to Treat CMV or AdV Reactivation or Disease in Patients After Solid Organ or Hematopoietic Stem Cell Transplantation (HCT)
Enrollment Status: Recruiting
Publish Date: November 19, 2025
Intervention Type: Biological
Study Phase: Early Phase 1
Phase II Study of Maintenance Ruxolitinib After Allogeneic Stem Cell Transplantation for Older Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) in Complete Remission
Phase II Study of Maintenance Ruxolitinib After Allogeneic Stem Cell Transplantation for Older Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) in Complete Remission
Enrollment Status: Active_not_recruiting
Publish Date: July 14, 2025
Intervention Type: Drug
Study Drug: Ruxolitinib
Study Phase: Phase 2
Phase I/II Clinical Trial of Daratumumab and Donor Lymphocyte Infusion in Patients With Relapsed Acute Myeloid Leukemia Post-Allogeneic Hematopoietic Stem Cell Transplant
Phase I/II Clinical Trial of Daratumumab and Donor Lymphocyte Infusion in Patients With Relapsed Acute Myeloid Leukemia Post-Allogeneic Hematopoietic Stem Cell Transplant
Enrollment Status: Terminated
Publish Date: May 21, 2025
Intervention Type: Procedure, Biological, Other
Study Drug: Daratumumab
Study Phase: Phase 1/Phase 2
A Phase I Clinical Trial Testing the Safety of IL-21-Expanded, Off-the-shelf, Third-party Natural Killer Cells (KDS-1001) for the Induction of Relapsed/Refractory Acute Myeloid Leukemia
A Phase I Clinical Trial Testing the Safety of IL-21-Expanded, Off-the-shelf, Third-party Natural Killer Cells (KDS-1001) for the Induction of Relapsed/Refractory Acute Myeloid Leukemia
Enrollment Status: Active_not_recruiting
Publish Date: February 07, 2025
Intervention Type: Biological, Drug
Study Drugs: Cytarabine, Cytarabine Hydrochloride, Decitabine, Fludarabine, Fludarabine Phosphate, Membrane-bound Interleukin-21-Expanded Haploidentical Natural Killer Cells
Study Phase: Phase 1
Tagraxofusp in Patients With Acute Myeloid Leukemia (AML) and Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Tagraxofusp in Patients With Acute Myeloid Leukemia (AML) and Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Enrollment Status: Completed
Publish Date: August 01, 2024
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 1 / 2 Study to Evaluate the Safety, Tolerability and Initial Anti-Tumor Activity of Adoptively Transferred T Lymphocytes Targeting WT1, PRAME and Cyclin A1 AML or MDS Patients With Relapsed Disease After Matched Allogeneic HCT
A Phase 1 / 2 Study to Evaluate the Safety, Tolerability and Initial Anti-Tumor Activity of Adoptively Transferred T Lymphocytes Targeting WT1, PRAME and Cyclin A1 AML or MDS Patients With Relapsed Disease After Matched Allogeneic HCT
Enrollment Status: Active_not_recruiting
Publish Date: January 16, 2024
Intervention Type: Biological
Study Drug: NEXI-001 T Cell Infusion
Study Phase: Phase 1/Phase 2
A Blinded, Prospective Non-Interventional Observational Study for the Evaluation of a GVHD Negative Outcome Score (GNOS) in Matched Unrelated or Haploidentical Hematopoietic Stem Cell Transplant
A Blinded, Prospective Non-Interventional Observational Study for the Evaluation of a GVHD Negative Outcome Score (GNOS) in Matched Unrelated or Haploidentical Hematopoietic Stem Cell Transplant
Enrollment Status: Completed
Publish Date: February 04, 2021
A Multi-Center, Phase II Cross-sectional Study Investigating Quality of Life in Older vs. Younger Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndromes: a Companion Study to the CIBMTR 10-CMSMDS-1-Approved Expanded Access Study
A Multi-Center, Phase II Cross-sectional Study Investigating Quality of Life in Older vs. Younger Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndromes: a Companion Study to the CIBMTR 10-CMSMDS-1-Approved Expanded Access Study
Enrollment Status: Completed
Publish Date: December 02, 2020
Intervention Type: Behavioral
Phase I Study of Decitabine and Haplo-identical Natural Killer Cells in Acute Myeloid Leukemia (AML)
Phase I Study of Decitabine and Haplo-identical Natural Killer Cells in Acute Myeloid Leukemia (AML)
Enrollment Status: Completed
Publish Date: March 09, 2020
Intervention Type: Other, Drug, Biological
Study Phase: Phase 1
A Phase 1b Dose-escalation Study of SGN-CD33A in Combination With Standard-of-care for Patients With Newly Diagnosed Acute Myeloid Leukemia
A Phase 1b Dose-escalation Study of SGN-CD33A in Combination With Standard-of-care for Patients With Newly Diagnosed Acute Myeloid Leukemia
Enrollment Status: Completed
Publish Date: May 09, 2018
Intervention Type: Drug
Study Phase: Phase 1
View 9 Less Clinical Trials

119 Total Publications

Successful engraftment in myeloablative transplant with cadaveric marrow after sudden unavailability of living donor.
Successful engraftment in myeloablative transplant with cadaveric marrow after sudden unavailability of living donor.
Journal: Blood advances
Published: October 24, 2025
Similar Doctors
Advanced in Agranulocytosis
Dr. Kavya M. Krishna
Hematology Oncology | Hematology | Oncology
Advanced in Agranulocytosis
Dr. Kavya M. Krishna
Hematology Oncology | Hematology | Oncology

Columbus Oncology Associates Inc

810 Jasonway Ave, Suite A, 
Columbus, OH 
 (3.9 miles away)
614-442-3130
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Kavya Krishna is a Hematologist Oncology specialist and a Hematologist in Columbus, Ohio. Dr. Krishna is rated as an Advanced provider by MediFind in the treatment of Agranulocytosis. Her top areas of expertise are Paget Disease of the Breast, Breast Cancer, Agranulocytosis, and Follicular Lymphoma. Dr. Krishna is currently accepting new patients.

Advanced in Agranulocytosis
Dr. Shabana J. Dewani
Hematology Oncology | Hematology | Oncology
Advanced in Agranulocytosis
Dr. Shabana J. Dewani
Hematology Oncology | Hematology | Oncology

Columbus Oncology Associates Inc

810 Jasonway Ave, Suite A, 
Columbus, OH 
 (3.9 miles away)
614-442-3130
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Shabana Dewani is a Hematologist Oncology specialist and a Hematologist in Columbus, Ohio. Dr. Dewani is rated as a Distinguished provider by MediFind in the treatment of Agranulocytosis. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Pleuropulmonary Blastoma, and Severe Congenital Neutropenia. Dr. Dewani is currently accepting new patients.

Advanced in Agranulocytosis
Dr. Emily B. Saul
Hematology Oncology | Hematology | Oncology
Advanced in Agranulocytosis
Dr. Emily B. Saul
Hematology Oncology | Hematology | Oncology

Columbus Oncology Associates Inc

810 Jasonway Ave, Suite A, 
Columbus, OH 
 (3.9 miles away)
614-442-3130
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Emily Saul is a Hematologist Oncology specialist and a Hematologist in Columbus, Ohio. Dr. Saul is rated as an Advanced provider by MediFind in the treatment of Agranulocytosis. Her top areas of expertise are Breast Cancer, Intraductal Papilloma, Familial Colorectal Cancer, and Chronic Familial Neutropenia. Dr. Saul is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Vasu's expertise for a condition
ConditionClose
View All 8 Distinguished Conditions
View All 10 Advanced Conditions
View All 39 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile